Short Interest in Enfusion, Inc. (NYSE:ENFN) Increases By 14.6%

Enfusion, Inc. (NYSE:ENFN) was the recipient of a large increase in short interest in the month of June. As of June 15th, there was short interest totalling 1,810,000 shares, an increase of 14.6% from the May 31st total of 1,580,000 shares. Currently, 3.7% of the company’s stock are short sold. Based on an average daily volume of 332,700 shares, the short-interest ratio is presently 5.4 days.

Analysts Set New Price Targets

A number of research analysts have weighed in on ENFN shares. Morgan Stanley began coverage on Enfusion in a research note on Friday, May 10th. They issued an “overweight” rating and a $11.00 price target for the company. Bank of America raised their target price on shares of Enfusion from $8.00 to $9.00 and gave the company an “underperform” rating in a research note on Wednesday, March 13th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $9.33.

Enfusion Trading Up 0.7 %

NYSE:ENFN traded up $0.06 on Wednesday, hitting $8.48. The company’s stock had a trading volume of 26,985 shares, compared to its average volume of 376,468. Enfusion has a one year low of $7.52 and a one year high of $11.56. The stock has a fifty day moving average of $9.04 and a two-hundred day moving average of $9.03. The firm has a market capitalization of $1.09 billion, a P/E ratio of 280.93, a price-to-earnings-growth ratio of 1.98 and a beta of 0.92.

Enfusion (NYSE:ENFN) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.05). Enfusion had a net margin of 1.40% and a return on equity of 6.60%. The business had revenue of $48.05 million during the quarter, compared to the consensus estimate of $47.67 million. During the same quarter last year, the company posted $0.04 EPS. As a group, sell-side analysts anticipate that Enfusion will post 0.09 EPS for the current year.

Insider Buying and Selling

In related news, insider Bronwen Bastone sold 18,241 shares of Enfusion stock in a transaction that occurred on Thursday, June 20th. The stock was sold at an average price of $8.11, for a total value of $147,934.51. Following the sale, the insider now owns 198,913 shares of the company’s stock, valued at approximately $1,613,184.43. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, Director Deirdre Somers sold 4,629 shares of the stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $8.40, for a total transaction of $38,883.60. Following the completion of the transaction, the director now directly owns 43,312 shares in the company, valued at approximately $363,820.80. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Bronwen Bastone sold 18,241 shares of Enfusion stock in a transaction dated Thursday, June 20th. The shares were sold at an average price of $8.11, for a total value of $147,934.51. Following the completion of the sale, the insider now directly owns 198,913 shares in the company, valued at approximately $1,613,184.43. The disclosure for this sale can be found here. In the last ninety days, insiders sold 36,318 shares of company stock valued at $296,688. Company insiders own 36.44% of the company’s stock.

Institutional Trading of Enfusion

A number of hedge funds have recently modified their holdings of ENFN. Allspring Global Investments Holdings LLC acquired a new position in Enfusion in the 1st quarter valued at $44,000. Tower Research Capital LLC TRC boosted its position in shares of Enfusion by 680.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 9,894 shares of the company’s stock valued at $96,000 after acquiring an additional 8,627 shares during the period. Barclays PLC grew its stake in shares of Enfusion by 29.0% in the third quarter. Barclays PLC now owns 10,809 shares of the company’s stock valued at $96,000 after acquiring an additional 2,430 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new position in Enfusion during the first quarter worth about $102,000. Finally, Quadrature Capital Ltd bought a new position in Enfusion during the first quarter worth about $109,000. Institutional investors and hedge funds own 81.05% of the company’s stock.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.